# Bonti

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bonti

- Industry: Biotechnology
- Headquarters: Newport Beach, US
- Website: www.bonti.com
- Total disclosed funding: $27M
- Latest round: Series C (Jan 23, 2018)
- Investors on record: 5

## About

Founded in 2015 and based in California, US, Bonti, Inc. is a biotechnology company that develops neurotoxins for therapeutic and aesthetic use. The company's CEO is Fauad Hasan, and CFO is David Ramsay, who served as CFO of Halozyme Therapeutics, Inc which is a public company. As of January 2018, the company has raised USD 36 million. 

The company's product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E) that is used for post-surgical pain. Though BoNT/E has a similar action mechanism to the marketed BoNT/A products, it has a differentiated clinical profile. The BoNT/E has a fast onset of action (within 24 hours) and a short duration of effect (about 3 to 4 weeks), while the BoNT/A has an onset of action around 3 to 7 days, and duration of effect around 3 to 4 months. BoNT/E can be used in aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain.

The company will use the Series C funding to continue developing EB-001, including a first Phase 2 pain study, LANTERN-1 (Long-Acting NeuroToxin-E Relief, Non-opioid), a second Phase 2 pain study (LANTERN-2), and preparing for an End of Phase 2 FDA meeting.

## Funding rounds

- Series C, Jan 23, 2018, $16M — City Hill Ventures, RBV Capital, Viva Ventures Biotech
- Series B, Apr 18, 2017, $12M — Colt Ventures, City Hill Ventures, HighLight Capital, RBV Capital, Viva Ventures Biotech

## Investors

- Colt Ventures (https://capitalatlas.ai/funds/colt-ventures) — Series B
- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series B, Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- RBV Capital — Series B, Series C
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series B, Series C